About Succipro

Our story

Succipro was founded in 2022 as a spin-off from the Pere Virgili Health Research Institute (IISPV) and Rovira i Virgili University (URV), driven by the desire to transform scientific discoveries into real therapeutic solutions. With a strong foundation in succinate research as a therapeutic target, we have evolved into a leader in the development of succinate-modulating drugs, aimed at treating metabolic and inflammatory diseases.

Our journey has been marked by collaboration with scientific institutions, pharmaceutical companies, and investors, enabling us to advance toward safe and effective solutions that transform patients’ lives.

Our team

We have a multidisciplinary team composed of researchers, scientists, doctors, and highly qualified professionals with extensive experience in drug development and the treatment of chronic diseases.

We work closely with internationally recognized specialists and collaborate with leading academic institutions to ensure that our projects remain at the forefront of scientific and pharmaceutical innovation.

Executive Team

Isabel Huber

PhD, MBA

CEO & Co-founder
Pharmacist with a PhD in Biochemistry from the University of Barcelona and an MBA in Biotechnology from Barcelona, with over 10 years of experience in preclinical research.

Sonia Fernández

PhD

CSO & Co-founder
Key opinion leader in succinate biology, with more than 100 publications and an H-index of 37 (according to Google Scholar), Principal Investigator of the DIAMET group.

Joan Vendrell

MD

CMO & Co-founder
Clinical Coordinator of the DIAMET research group. Head of the Endocrinology Department at the Joan XXIII University Hospital and Professor at Rovira i Virgili University.

Vicenç Tur

MBA

CBO
Bachelor’s in Business Administration (UIB) and Economics (UAB), in addition to holding an MBA. He has extensive experience in managing R&D projects in innovative companies, with over 20 years as (co)founder, CEO, CFO, and CBO.

R&D Team

Sara Notararigo

PhD, MBA

Project Manager
A distinguished professional in the field of biotechnology. Her doctoral thesis was developed in in vivo models of Crohn’s disease, investigating the immunomodulatory effects of beta-glucans.

Carme Grau

PhD

Preclinical Drug Discovery Scientist
Biochemist and PhD in Nutrition and Metabolism from URV, leading the innovative project on succinate-consuming enzymes, funded by the Torres Quevedo program.

Marjorie Reyes

PhD

Drug Discovery Scientist
Professional with over 10 years of experience in scientific research with a translational approach. Her career includes studies on inflammation, drug development, and metabolic and intestinal diseases.

External Advisors

Manuel Barreiro

External Clinical Advisor
Head of the Inflammatory Bowel Disease (IBD) Unit at the University Clinical Hospital of Santiago de Compostela, Spain, and was President of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) from 2019 to 2021. He is also a member of the European Crohn’s and Colitis Organization (ECCO) and the ECCO Education Committee (EDUCOM).

Maribel Berges

Chemical Engineer
Chemical Engineer from the Institut Químic de Sarrià, a degree in Organic Chemistry from the University of Ramon Llull, and an MBA from IESE. She has extensive experience in the sector, including a distinguished career at the Bosch i Gimpera Foundation and the Technology Transfer Office at the University of Barcelona.

José Manuel Fernández-Real

Endocrinologist, MD
Endocrinologist and Researcher at the Dr. Josep Trueta Biomedical Research Institute in Girona. With over 25 years of experience studying obesity, insulin resistance, and related metabolic disorders.

Subscribe to our Newsletter!

Scroll to Top